Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for …

BACKGROUND: There is ambiguity whether frail patients with atrial fibrillation managed with
vitamin K antagonists (VKAs) should be switched to a non–vitamin K oral anticoagulant …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Abstract Background and Objective Drug–drug interactions between direct oral
anticoagulants (DOAC) and antiseizure medications via the cytochrome P450 (CYP) or the P …

To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …

A real‐world association between direct oral anticoagulant (DOAC) concentration and
clinical outcomes among Asian patients with atrial fibrillation (AF) is reported herein …

Balancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is
challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for …

Background Studies have shown that patients with non-valvular atrial fibrillation (NVAF) who
discontinue oral anticoagulants (OACs) are at higher risk of complications such as stroke …